Yes, absolutely, Mr. Lauzon.
Thank you for that question.
The main impact would be that we would no longer be able to continue working on our projects, the clinical trials projects. We would no longer be able to fund new projects and we would no longer be able to attract others. For example, when our budget was cut by 40%, in 2020, we had to completely cut out the first stage of our product development pipeline, because we unfortunately didn't have enough money to sustain it. What did we do? We continued to invest in the products we had already invested in, to try to get them to clinical trials.
If there were to be a period in which there was no funding, that would result not only in departures from the BioCanRx team itself, but also in a loss of continuity in the projects. It would jeopardize the engine we have built, which is working really very well, for evaluating the technologies and moving them toward clinical trials.
So it would cause a total stoppage of these types of activities. That would have a major impact, sir.